VON Complete Dashboard 2024 - All Key Performance Measures

Data: VON Annual Report 2024 | N = 34 infants (VLBW ≤1500g or ≤29w6d)

🎯 POSIZIONAMENTO GENERALE: Top Performer VON Network (71% metriche sopra mediana)

—

—

—

3. DISCHARGE OUTCOMES & GROWTH - Control Chart ===== 📈 Discharge Quality & Growth Parameters ===== <achart> { "chart": { "type": "radar", "height": 450 }, "title": { "text": "Discharge Outcomes Quality - Centro 297 vs Network", "align": "center" }, "series": [ { "name": "Centro 297 (Actual)", "data": [61.3, 100, 100, 71.4, 96.4, 85.7, 57.1] }, { "name": "VON Median (Target)", "data": [63.0, 95.1, 95.5, 72.7, 88.1, 70.0, 69.6] }, { "name": "Q1 Excellence", "data": [50.0, 100, 100, 81.1, 95.0, 80.0, 60.0] } ], "xaxis": { "categories": [ "Any Human Milk %", "No Oxygen %", "No Monitor %", "Weight >3rd %", "Head Circ >3rd %", "Weight >10th %", "Head Circ >10th %" ] }, "yaxis": { "min": 0, "max": 100 }, "colors": ["#DC3545", "#28A745", "#0066CC"], "markers": { "size": 6 }, "legend": { "position": "top" } } </achart> ==== Discharge Quality Metrics ==== ^ Metrica ^ Centro 297 (%) ^ VON Median (%) ^ Quartile ^ Target ^ Performance ^ | **Any Human Milk** | 61.3 | 63.0 | 🟡 Q1-Q2 | >50% | ✅ BUONA | | **Oxygen at Discharge** | 0.0 | 4.9 | 🟢 **Q1** | 0% | ✅ ECCELLENTE | | **Monitor at Discharge** | 0.0 | 4.5 | 🟢 **Q1** | 0% | ✅ ECCELLENTE | | **Discharge Weight >3rd** | 71.4 | 72.7 | 🟡 Q2-Q3 | >70% | ✅ BUONA | | **Head Circumference >3rd** | 96.4 | 88.1 | 🟢 **Q1** | >80% | ✅ ECCELLENTE | | **Discharge Weight >10th** | 57.1 | 50.0 | 🟡 Q1-Q2 | >50% | ✅ BUONA | | **Head Circumference >10th** | 85.7 | 69.6 | 🟢 **Q1** | >70% | ✅ ECCELLENTE | --- 4. LENGTH OF STAY ANALYSIS

📊 Length of Stay Performance: - Home: 57 days vs 70 median (-13 days - MIGLIORE) - Transfer: 44 days vs 49 median (-5 days - MIGLIORE) - Overall: 55 days vs 59 median (-4 days - EFFICIENTE)

—

5. COMPREHENSIVE SCORECARD ===== 🎯 Complete Performance Matrix - All 17 Measures ===== ==== Green Zone: Excellence (Q1 Performance) ==== ^ Metrica ^ Centro 297 ^ VON Q1 ^ Status ^ Maintained Since ^ | **Mortality** | 2.9% | ≤8.3% | ✅ **TOP 25%** | 2024 breakthrough | | **Mortality Excluding Early** | 2.9% | ≤4.5% | ✅ **TOP 25%** | 2024 breakthrough | | **Chronic Lung Disease** | 11.1% | ≤11.1% | ✅ **TOP 25%** | 2024 recovery | | **Cystic PVL** | 0.0% | ≤0.0% | ✅ **TOP 25%** | Consistently excellent | | **Severe ROP** | 0.0% | ≤0.0% | ✅ **TOP 25%** | Consistently excellent | | **Oxygen at Discharge** | 0.0% | ≤0.0% | ✅ **TOP 25%** | Consistently excellent | | **Monitor at Discharge** | 0.0% | ≤0.0% | ✅ **TOP 25%** | Consistently excellent | | **Head Circumference >3rd** | 96.4% | ≥95.0% | ✅ **TOP 25%** | Growth excellence | ==== Yellow Zone: Above Median (Q1-Q2 Performance) ==== ^ Metrica ^ Centro 297 ^ VON Median ^ Gap ^ Trend ^ | **Death or Morbidity** | 35.3% | 41.2% | **-5.9** | ✅ Better than median | | **Any Late Infection** | 5.9% | 8.2% | **-2.3** | ✅ Better than median | | **Severe IVH** | 5.9% | 6.0% | **-0.1** | ✅ At median | | **Any Human Milk** | 61.3% | 63.0% | **-1.7** | ⚠️ Slightly below | ==== Orange Zone: Below Median (Q2-Q3 Performance) ==== ^ Metrica ^ Centro 297 ^ VON Median ^ Gap ^ Action Needed ^ | **Discharge Weight >3rd** | 71.4% | 72.7% | **-1.3** | 🟡 Minor concern | | **Discharge Weight >10th** | 57.1% | 50.0% | **+7.1** | ✅ Actually good | | **Head Circumference >10th** | 85.7% | 69.6% | **+16.1** | ✅ Actually excellent | ==== Red Zone: Critical Areas (Q4 Performance) ==== ^ Metrica ^ Centro 297 ^ VON Median ^ Gap ^ Priority ^ | **Necrotizing Enterocolitis** | 14.7% | 3.4% | **+11.3** | 🚨 **URGENT** | | **Pneumothorax** | 11.8% | 2.9% | **+8.9** | 🚨 **HIGH** | --- 6. STRATEGIC DASHBOARD & ACTION PLAN

🚨 NECROTIZING ENTEROCOLITIS - Immediate Action - Current: 14.7% vs 3.4% VON (Q4 - Bottom 25%) - Target: <7% by Q2 2025 (move to Q2-Q3) - Actions:

1. [ ] Emergency review feeding protocols
2. [ ] Audit antibiotic prophylaxis guidelines
3. [ ] Staff retraining on early recognition
4. [ ] Weekly case reviews for 6 months

⚠️ PNEUMOTHORAX - Protocol Review - Current: 11.8% vs 2.9% VON (Q4 - Bottom 25%) - Target: <6% by Q3 2025 (move to Q2-Q3) - Actions:

1. [ ] Ventilation strategy review
2. [ ] Surfactant administration protocols
3. [ ] Respiratory therapy training update

✅ MORTALITY LEADERSHIP - Achievement: Q1 performance in both metrics - Maintain: Continue protocols that achieved breakthrough - Share: Document best practices for network

✅ CHRONIC LUNG DISEASE RECOVERY - Achievement: From Q4 (2023) to Q1 (2024) - Maintain: Current ventilation strategies - Monitor: Prevent regression to previous levels

✅ DISCHARGE QUALITY - Achievement: Q1 in 3/4 discharge metrics - Optimize: Human milk to reach >65% - Maintain: Zero oxygen/monitor discharges

📈 HUMAN MILK OPTIMIZATION - Current: 61.3% vs 63.0% VON - Target: >70% by end 2025 - Strategy: Leverage existing lactation protocols

📊 BENCHMARKING LEADERSHIP - Goal: Achieve Q1 performance in >80% metrics - Current: 47% Q1 performance - Timeline: 18-month improvement plan

Q2 2025 Targets: - ✅ NEC: <7% (from 14.7%) - ✅ Pneumothorax: <6% (from 11.8%) - ✅ Maintain all current Q1 metrics - ✅ Human Milk: >65%

Year-End 2025 Goal: - 🎯 >75% metrics in Q1-Q2 (vs current 71%) - 🎯 Zero Q4 metrics (vs current 2) - 🎯 VON Network Top 10% overall ranking

🟢 EXCELLENT (8 metrics): Mortality, CLD, PVL, ROP, Discharge Support, Growth 🟡 GOOD (7 metrics): Morbidity, Infection, IVH, Human Milk, Weights 🔴 CRITICAL (2 metrics): NEC, Pneumothorax

Overall Grade: B+ (Excellent with 2 critical areas) Network Ranking: Estimated Top 25% 2025 Goal: A- (Top 10% with all areas resolved)